Association of PPAR-γ2 and β3-AR Polymorphisms With Postmenopausal Hypertension

Journal of Clinical Hypertension

Volumn 17, Issue 7, 2015, Pages 549-556

  Grygiel Górniak, Bogna ^a   Kaczmarek, Elzbieta ^a   Mosor, Maria ^b   Przysławski, Juliusz ^a   Nowak, Jerzy ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

AGED; BLOOD; BLOOD PRESSURE; CALORIC INTAKE; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POSTMENOPAUSE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; ENERGY INTAKE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PPAR GAMMA; RECEPTORS, ADRENERGIC, BETA-3; TRIGLYCERIDES;

EID: 84934444078     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12537     Document Type: Article

References (43)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
2. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
3. Grygiel-Górniak B, Marcinkowska J, Szczepanik A, Przysławski J. Nutritional habits and oxidative stress in postmenopausal age. Pol Arch Med Wewn. 2014;124:298-305.
4. Weber MA, Bakris GL, Hester A, et al. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013;126:501-508.
5. Rossi P, Frances Y, Kingwell BA, Ahimastos AA. Gender differences in artery wall biomechanical properties throughout life. J Hypertens. 2011;29:1023-1033.
6. Thompson J, Khalil RA. Gender differences in the regulation of vascular tone. Clin Exp Pharmacol Physiol. 2003;30:1-15.
7. Zheng Y, Sun Q, Chen K, et al. Waist-to-hip ratio, dyslipidemia, glycemic levels, blood pressure and depressive symptoms among diabetic and non-diabetic Chinese women: a cross-sectional study. PLoS One. 2014;10:e109765.
8. Thomas F, Pannier B, Benetos A, Vischer UM. Visceral obesity is not an independent risk factor of mortality in subjects over 65 years. Vasc Health Risk Manag. 2013;9:739-745.
9. Saltiki K, Cimponeriu A, Lili K, et al. Severity of coronary artery disease in postmenopausal diabetic women. Hormones (Athens). 2008;7:148-155.
10. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. Hypertension. 2009;54:375-383.
11. Ruiz-Narváez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr. 2007;86:1238-1242.
12. Evans D, de Heer J, Hagemann C, et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001;109:151-154.
13. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications.A review. Nutr J. 2014;13:17.
14. Leibovitz E, Schiffrin EL. The many faces of PPARgamma. Cell. 2005;123:993-999.
15. Leibovitz E, Schiffrin EL. PPAR activation: a new target for the treatment of hypertension. J Cardiovasc Pharmacol. 2007;50:120-125.
16. Rodríguez-Esparragón FJ, Rodríguez-Pérez JC, Macías-Reyes A, Alamo-Santana F. Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens. 2003;21:1649-1655.
17. Frederiksen L, Brodbaek K, Fenger M, et al. Studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002;87:3989-3992.
18. Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002;147:495-501.
19. Poirier O, Nicaud V, Cambien F, Tiret L. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J Mol Med. 2000;78:346-351.
20. Hasstedt SJ, Ren QF, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-{gamma}2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab. 2001;86:536-541.
21. WHO. World Health Organization Diet, nutrition and the prevention of chronic diseases. WHO Technical Report Series 916 chapter 5 Geneva 2003.
22. O'Brien E, Asmar R, Beilin L, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-848.
23. Nichols WW, O'Rourke MF. Theoretical, Experimental and Clinical Principles. McDonald's Blood Flow in Arteries. London, England; Edward Arnold; 2006:49-94, 193-233, 339-402.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
26. Charzewska J. Instruction of the Dietary Recall Gathering from the Last 24 Hours. Warsaw (in Polish): Press National Food and Nutrition Institute; 1998.
27. Kunachowicz H, Nadolna I, Przygoda B, Iwanow K. Tables of Nutritious Value of Food Products. Warsaw (in Polish): Press National Food and Nutrition Institute; 1998.
28. Przysławski J, Walkowiak J, Gertig H, et al. Nutritional value of daily food rations (DFR's) taken by cystic fibrosis children. Pediatr Pol. 1998;73:399-405.
29. Jarosz M, Bulhak-Jachymczyk B. Recommended Values of Human Nutrition. The Background of Obesity and Non-Communicable Diseases Prevention. Warsaw (in Polish): Medical Publishing Company PZWL; 2008.
30. Sivenius K, Valve R, Lindi V, et al. Synergistic effect of polymorphisms in uncoupling protein 1 and_3-adrenergic receptor genes on long-term body weight change in Finnish type 2 diabetic and non-diabetic control subjects. Int J Obes Relat Metab Disord. 2000;24:514-519.
31. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.
32. Katz EG, Stevens J, Truesdale KP, et al. Associations of body mass index with incident hypertension in American white, American black and Chinese Asian adults in early and middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Atherosclerosis Risk in Communities (ARIC) study and the People's Republic of China (PRC) study. Asia Pacific J Clin Nutr. 2013;22:626-634.
33. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J. 1999;138:205-210.
34. Weber MA, Bakris GL, Neutel JM, et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003;5:322-329.
35. Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
36. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci. 2009;5:3-9.
37. Smulyan H, Asmar RG, Rudnicki A, et al. Comparative effects of aging in men and women on the properties of the arterial tree. J Am Coll Cardiol. 2001;37:1374-1380.
38. Regnault V, Thomas F, Safar ME, et al. Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;59:1771-1777.
39. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep. 2001;3:152-156.
40. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance in its history. J Hypertens. 2006;24:621-626.
41. Palomo L, Félix-Redondo FJ, Lozano-Mera L, et al. Cardiovascular risk factors, lifestyle, and social determinants: a cross-sectional population study. Br J Gen Pract. 2014;64:e627-e633.
42. Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blond pressure regulation. Am J Hypertens. 2004;17:994-1001.
43. Mitu F, Cobzaru R, Leon MM. Influence of metabolic syndrome profile on cardiovascular risk. Rev Med Chir Soc Med Nat Iasi. 2013;117:308-314.